Literature DB >> 15739824

Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.

Per-Anders Mårdh1, Jolanta Wågström, Maria Landgren, Jan Holmén.   

Abstract

BACKGROUND: The epidemiology of vulvovaginal candidiasis (VVC) and such recurrent infections (RVVC) has been difficult to study as the majority of episodes of these conditions are self-treated by the women affected. In Sweden, all pharmacies are owned by the state and all prescriptions and over-the-counter (OTC) products, such as antifungals, are registered in a database, which offers unique possibilities to study the epidemiology of VVC/RVVC.
OBJECTIVES: To analyze all prescriptions and OTC products purchased for therapy of VVC/RVVC and to establish reasons for any observed variation in the sales figures.
METHODS: Sales figures in the Swedish county of Skåne of antifungal drugs for therapy of VVC/RVVC were analyzed by the aid of the 'ACS' database of the National Corporation of Swedish Pharmacies for the years 1990--1999. The size of the female population in the county is approximately half a million.
RESULTS: The study showed that 93% of all antifungal drugs for VVC/RVVC were sold as OTC products. An increase in sales of the drugs occurred until mid- 1993/94, followed by a decrease until end of the study period in 1999. Demographic factors (e.g. the number of female inhabitants in the county, pharmacies and health-care units), the pregnancy rate and pharmacy-dependent factors (such as the introduction of shelves for self-selection of antifungal products) did not explain the observed variations in sales. Distinct short-term variations in the number of prescriptions of fluconazole and itraconazole could be explained by drugs company sales campaigns and logistics factors in drug distribution. The sales volumes in the 33 municipalities in the county correlated with the density of the population, which was not the case for the total number of prescriptions made in the county during the 1990s. The variation in antifungal drug sales was similar to that of hormonal intrauterine devices, but this was not the case for oral contraceptives. The total Swedish usage of antibiotics showed a similar variation to that of the antifungal drugs analyzed.
CONCLUSION: The study stresses the limited impact on the treatment of VVC/RVVC by the medical community. Behavior-related factors in the female population are the most likely explanation for the marked variations found in the usage of drugs for the two conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15739824      PMCID: PMC1784592          DOI: 10.1080/10647440400003972

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  16 in total

1.  Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns.

Authors:  S Sihvo; R Ahonen; H Mikander; E Hemminki
Journal:  Fam Pract       Date:  2000-04       Impact factor: 2.267

2.  In vitro effect of fibrinogen on Candida albicans germ tube formation.

Authors:  A Rodrigues; C P Vaz; P A Mårdh; A F da Fonseca; J M de Oliveira
Journal:  APMIS       Date:  1999-11       Impact factor: 3.205

3.  Is the lack of concurrence of bacterial vaginosis and vaginal candidosis explained by the presence of bacterial amines?

Authors:  A G Rodrigues; P A Mârdh; C Pina-Vaz; J Martinez-de-Oliveira; A F da Fonseca
Journal:  Am J Obstet Gynecol       Date:  1999-08       Impact factor: 8.661

4.  Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner.

Authors:  J J Calderón-Márquez
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

5.  Psychological factors associated with recurrent vaginal candidiasis: a preliminary study.

Authors:  G Irving; D Miller; A Robinson; S Reynolds; A J Copas
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

6.  Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species.

Authors:  Cidália Pina-Vaz; Filipe Sansonetty; Acácio G Rodrigues; J Martinez-DE-Oliveira; António F Fonseca; Per-Anders Mårdh
Journal:  J Med Microbiol       Date:  2000-09       Impact factor: 2.472

7.  Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis.

Authors:  Per-Anders Mårdh; Natalia Novikova; Elena Stukalova
Journal:  BJOG       Date:  2003-10       Impact factor: 6.531

8.  Ketoconazole in the prevention of experimental candidal vaginitis.

Authors:  J D Sobel; G Muller
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

9.  Comparison of econazole and clotrimazole in the treatment of vulvovaginal candidiasis.

Authors:  D Brown; G L Binder; H L Gardner; J Wells
Journal:  Obstet Gynecol       Date:  1980-07       Impact factor: 7.661

Review 10.  Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy.

Authors:  Per-Anders Mårdh; Acacio G Rodrigues; Mehmet Genç; Natalia Novikova; J Martinez-de-Oliveira; Secondo Guaschino
Journal:  Int J STD AIDS       Date:  2002-08       Impact factor: 1.359

View more
  2 in total

1.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

Review 2.  Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion.

Authors:  Gilbert Donders; István Oszkár Sziller; Jorma Paavonen; Phillip Hay; Francesco de Seta; Jean Marc Bohbot; Jan Kotarski; Jordi Antoni Vives; Bela Szabo; Ramona Cepuliené; Werner Mendling
Journal:  Front Cell Infect Microbiol       Date:  2022-09-09       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.